Aug 25 2026 09:30 PM EST

Hims & Hers Rallies on Weight-Loss Program Launch and Raised Revenue Outlook

Hims & Hers Health, Inc. (NYSE: HIMS) shares have climbed 23.3% over the past five days after the company unveiled a prescription weight-loss program, raised its full-year revenue guidance, and saw demand for new offerings outpace internal forecasts. The stock’s advance was also supported by favorable FDA guidance for telehealth-based prescriptions, a surge in new subscriber signups, and a wave of analyst price target increases, reinforcing optimism around the company’s growth trajectory and sector leadership.

Weight-Loss Launch and Regulatory Tailwinds Drive Sentiment

The company’s announcement on August 22 of a new prescription weight-loss program—including compounded GLP-1 medications—was a central catalyst for the latest rally. Early demand significantly exceeded internal forecasts, with more than 25,000 sign-ups in the first 48 hours. This development coincided with the FDA’s updated guidance (August 23) supporting broader telehealth-based prescription renewals, a move widely seen as favorable for digital health platforms such as Hims & Hers.

Positive sentiment was reinforced by the company’s upward revision to full-year revenue guidance, now set at $3.1–$3.3 billion—a 32%–41% increase year-on-year—reflecting strong demand, robust subscriber retention, and rapid international expansion. Several Wall Street analysts raised their price targets following the news, with Goldman Sachs and Morgan Stanley citing the successful launch of the weight-loss program, subscriber growth, and supportive regulatory conditions.

Financial Results Highlight Subscriber Momentum and Revenue Scale

Second-quarter results, reported August 10, further underpinned the market’s positive reaction. Revenue increased 38% year-on-year to $753.2 million, while the active subscriber base expanded by 300,000 net additions in the quarter, reaching nearly 2.9 million. International revenue surged 17-fold year-on-year to $131.4 million, driven by the Eucalyptus acquisition and strong performance in Australia, the UK, and Germany.

Adjusted EBITDA for the quarter was $60–$60.3 million (an 8% margin), and operating cash flow remained positive at $53.4 million for the first half. However, the company reported a net loss of $86 million for the quarter, reflecting higher operating expenses, restructuring and legal costs. Gross margin compressed to 64% from 76% a year earlier, due to a product mix shift toward branded weight-loss and international sales.

Sector Tailwinds and Competitive Position

Broader sector momentum and favorable macroeconomic trends have also played a role. The global telehealth market continues to expand, with the U.S. remaining a leader in digital health adoption. Recent FDA guidance supporting online prescription renewals and increased consumer demand for weight management and preventive health products have provided additional tailwinds.

Hims & Hers has distinguished itself through its direct-to-consumer subscription model, vertically integrated pharmacy operations, rapid international expansion, and investments in AI-powered care. The company’s platform now covers multiple health specialties, with cross-selling opportunities and high retention in weight-loss and hormonal health segments.

Risks: Regulatory Scrutiny, Margin Pressure and Competition

While Hims & Hers’ momentum and execution in high-growth health categories have fueled recent share gains, the company faces a complex regulatory and competitive environment. Margin pressure from the product mix shift and expanded operations, as well as the outcome of regulatory and legal proceedings, remain critical variables for investors. Whether the company can translate subscriber and revenue growth into sustained profitability will likely determine the durability of its current market re-rating.